Literature DB >> 19572115

Molecular pathogenesis of spinocerebellar ataxia type 1 disease.

Seongman Kang1, Sunghoi Hong.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is an autosomal-dominant neurodegenerative disorder characterized by ataxia and progressive motor deterioration. SCA1 is associated with an elongated polyglutamine tract in ataxin-1, the SCA1 gene product. As summarized in this review, recent studies have clarified the molecular mechanisms of SCA1 pathogenesis and provided direction for future therapeutic approaches. The nucleus is the subcellular site where misfolded mutant ataxin-1 acts to cause SCA1 disease in the cerebellum. The role of these nuclear aggregates is the subject of intensive study. Additional proteins have been identified, whose conformational alterations occurring through interactions with the polyglutamine tract itself or non-polyglutamine regions in ataxin-1 are the cause of SCA-1 cytotoxicity. Therapeutic hope comes from the observations concerning the reduction of nuclear aggregation and alleviation of the pathogenic phenotype by the application of potent inhibitors and RNA interference.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19572115     DOI: 10.1007/s10059-009-0095-y

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  12 in total

1.  A conserved eEF2 coding variant in SCA26 leads to loss of translational fidelity and increased susceptibility to proteostatic insult.

Authors:  Katherine E Hekman; Guo-Yun Yu; Christopher D Brown; Haipeng Zhu; Xiaofei Du; Kristina Gervin; Dag Erik Undlien; April Peterson; Giovanni Stevanin; H Brent Clark; Stefan M Pulst; Thomas D Bird; Kevin P White; Christopher M Gomez
Journal:  Hum Mol Genet       Date:  2012-09-21       Impact factor: 6.150

2.  A Drosophila model of the neurodegenerative disease SCA17 reveals a role of RBP-J/Su(H) in modulating the pathological outcome.

Authors:  Jie Ren; Anil G Jegga; Minlu Zhang; Jingyuan Deng; Junbo Liu; Christopher B Gordon; Bruce J Aronow; Long J Lu; Bo Zhang; Jun Ma
Journal:  Hum Mol Genet       Date:  2011-06-08       Impact factor: 6.150

Review 3.  Sleep Disorders in Hereditary Ataxias.

Authors:  Lucio Huebra; Fernando Morgadinho Coelho; Flávio Moura Rezende Filho; Orlando G Barsottini; José Luiz Pedroso
Journal:  Curr Neurol Neurosci Rep       Date:  2019-07-25       Impact factor: 5.081

4.  An out-of-frame overlapping reading frame in the ataxin-1 coding sequence encodes a novel ataxin-1 interacting protein.

Authors:  Danny Bergeron; Catherine Lapointe; Cyntia Bissonnette; Guillaume Tremblay; Julie Motard; Xavier Roucou
Journal:  J Biol Chem       Date:  2013-06-12       Impact factor: 5.157

5.  FOX-2 dependent splicing of ataxin-2 transcript is affected by ataxin-1 overexpression.

Authors:  Franziska Welzel; Christian Kaehler; Melanie Isau; Linda Hallen; Hans Lehrach; Sylvia Krobitsch
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

6.  Temporal retinal nerve fiber loss in patients with spinocerebellar ataxia type 1.

Authors:  Sarah Stricker; Timm Oberwahrenbrock; Hanna Zimmermann; Jan Schroeter; Matthias Endres; Alexander U Brandt; Friedemann Paul
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

Review 7.  Gene, Stem Cell, and Alternative Therapies for SCA 1.

Authors:  Jacob L Wagner; Deirdre M O'Connor; Anthony Donsante; Nicholas M Boulis
Journal:  Front Mol Neurosci       Date:  2016-08-12       Impact factor: 5.639

8.  Ataxin-1 is involved in tumorigenesis of cervical cancer cells via the EGFR-RAS-MAPK signaling pathway.

Authors:  A-Ram Kang; Hyoung-Tae An; Jesang Ko; Eui-Ju Choi; Seongman Kang
Journal:  Oncotarget       Date:  2017-10-10

Review 9.  Regulation and function of capicua in mammals.

Authors:  Yoontae Lee
Journal:  Exp Mol Med       Date:  2020-04-01       Impact factor: 8.718

10.  Minimotifs dysfunction is pervasive in neurodegenerative disorders.

Authors:  Surbhi Sharma; Richard J Young; Jingchun Chen; Xiangning Chen; Edwin C Oh; Martin R Schiller
Journal:  Alzheimers Dement (N Y)       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.